Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc (ONCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,993
  • Shares Outstanding, K 2,689
  • Annual Sales, $ 790 K
  • Annual Income, $ -39,480 K
  • 60-Month Beta 1.26
  • Price/Sales 30.35
  • Price/Cash Flow N/A
  • Price/Book 0.84
Trade ONCT with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 73.85%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.88
  • Number of Estimates 4
  • High Estimate -2.46
  • Low Estimate -3.30
  • Prior Year -4.00
  • Growth Rate Est. (year over year) +28.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.00 +9.56%
on 03/28/24
9.85 -11.03%
on 04/02/24
+0.55 (+6.63%)
since 03/22/24
3-Month
6.69 +31.01%
on 01/24/24
10.61 -17.41%
on 03/01/24
+1.87 (+27.03%)
since 01/23/24
52-Week
5.57 +57.49%
on 01/08/24
13.14 -33.30%
on 12/22/23
+2.20 (+33.61%)
since 04/21/23

Most Recent Stories

More News
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.76% and 1.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ONCT : 8.77 (+2.51%)
CRON : 2.47 (+4.66%)
Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?

Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.

ACAD : 16.74 (-1.47%)
ONCT : 8.77 (+2.51%)
AKRO : 21.00 (+1.01%)
VTRS : 11.36 (+0.98%)
United Therapeutics (UTHR) Q1 Earnings Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 234.47 (+0.18%)
ONCT : 8.77 (+2.51%)
Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NKTR : 1.4200 (+4.41%)
ONCT : 8.77 (+2.51%)
The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals

bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.

VRTX : 404.91 (+1.25%)
RNA : 25.14 (+4.06%)
BLUE : 0.9706 (+1.78%)
ASND : 144.83 (+1.92%)
ONCT : 8.77 (+2.51%)
Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates

Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.

VRTX : 404.91 (+1.25%)
RNA : 25.14 (+4.06%)
BLUE : 0.9706 (+1.78%)
ASND : 144.83 (+1.92%)
ONCT : 8.77 (+2.51%)
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway

Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.

AZN : 70.85 (+1.03%)
NVO : 128.64 (+2.70%)
LGND : 69.89 (+1.98%)
ONCT : 8.77 (+2.51%)
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 144.68 (+1.85%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 0.7420 (+2.93%)
AMC : 3.39 (-0.88%)
ONCT : 8.77 (+2.51%)
EVO : 7.65 (+3.94%)
HLN : 8.41 (+0.60%)
CRBG : 27.33 (+0.92%)
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

AQST : 4.28 (-2.28%)
ONCT : 8.77 (+2.51%)
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ONCT : 8.77 (+2.51%)
ASRT : 0.9095 (+5.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Oncternal Therapeutics Inc. is a clinical-stage oncology company. It is engaged in developing treatments for cancers with critical unmet medical need. The company's pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 9.47
2nd Resistance Point 9.24
1st Resistance Point 9.00
Last Price 8.77
1st Support Level 8.53
2nd Support Level 8.30
3rd Support Level 8.06

See More

52-Week High 13.14
Fibonacci 61.8% 10.25
Fibonacci 50% 9.35
Last Price 8.77
Fibonacci 38.2% 8.46
52-Week Low 5.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar